Skip to main content

CAR T Cells

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

  • RegistryNCT02917083
  • PhasePhase 1
  • StatusRecruiting
  • ConditionHodgkin's Lymphoma
  • SponsorBaylor College of Medicine
How RELY-30 worksNCT029170831 min

What the film says

Read the transcript

Hodgkin lymphoma is usually cured. When it keeps returning after chemotherapy, antibodies, and transplant, the choices thin out.

The idea: take the antibody that already targets Hodgkin cells, and bolt it onto the patient's own T cells.

Hodgkin cells carry a marker called CD30. Antibody drugs against it help but rarely cure. Here, T cells from the patient's blood receive a gene that mounts the anti-CD30 antibody on their surface, so each cell hunts on its own. One infusion, after chemotherapy clears room.

In forty-one heavily treated patients at two centers, side effects were mostly on blood counts, and after fludarabine-based chemotherapy, seven in ten responded, most completely.

RELY-30, at Baylor, led by Carlos Ramos, now tests higher doses. Public record; not medical advice.

Sources behind this film

  • PaperAnti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

    Ramos CA. J Clin Oncol, 2020

    Hodgkin lymphoma usually cured; relapse after chemo, antibodies, transplant; 41 patients, two centers; mostly hematologic toxicity; 72% overall response, 59% complete after fludarabine-based lymphodepletion

  • ClinicalTrials.gov record NCT02917083

    Hodgkin lymphoma usually cured; relapse after chemo, antibodies, transplant; CD30 marker; anti-CD30 antibody drugs help but rarely cure; Gene mounts the anti-CD30 antibody on the T cells; one infusion after lymphodepleting chemotherapy; Higher doses; Carlos Ramos, Baylor

The drug

What is being tested.

Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule: Dose Level One: 2x10^7 cells/m2.

To prepare the CD30.CAR T cells, research staff will take some blood from the subject. This would be drawn as two separate blood collections. Alternatively, if the subject's blood counts are low, staff may collect the cells needed to prepare T cells by a pheresis procedure. This procedure will involve placing a needle in both arms, collecting the cells over 3 to 6 hours during which the subject will be required to lie relatively still.

After the T cells have been collected, some of them will be activated stimulating them with antibodies and will then be infected with a retroviral vector (a special virus that can carries a new gene into cells) containing a new gene called anti-CD30 that will make an antibody to lymphoma cells. The trained cells are called CD30.CAR T cells. Then, the cells will be tested to make sure that they kill lymphoma cells that express the CD30 antigen and not normal cells.

The study

How the trial runs.

The subject has a type of lymph gland cancer called Lymphoma. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs.

Both antibodies and T cells have been used to treat patients with cancers; they both have shown promise, but have not been strong enough to cure most patients. Investigators hope that both will work better together. Investigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • PROCUREMENT Inclusion Criteria:
  • Diagnosis of relapsed/refractory HL or NHL.
  • CD30 positive tumor as assayed in a CLIA certified pathology laboratory (result can be pending at this time)
  • Hgb ≥ 7.0 (may be a transfused value)
  • Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent.
  • Karnofsky or Lansky score of > 60%

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.